Trial
NCT02906605
A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Janssen Research & Development, LLC
Collaborators
—
Condition
Prostatic Neoplasms, Castration-Resistant
Intervention
JNJ-809
Why stopped
Study start delayed due to pending collection and analysis of additional phase 1 data.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-11-22